Background: Loss of muscle mass and function are major clinical phenomena 1 affecting most advanced cancer patients. Recent work shows that defects in 2 muscle regeneration contribute to cancer-associated wasting. Among the factors 3 implicated in wasting-associated suppression of muscle regeneration are 4 cytokines that interfere with myogenic signal transduction pathways. Less 5 understood is how other cancer/wasting-associated cues, such as 6 oncometabolites, contribute to muscle dysfunction. This study investigates how 7 the oncometabolite succinate affects myogenesis and muscle regeneration. 8
INTRODUCTION 28
Lean mass (muscle) loss and functional skeletal muscle decline affect the 29 majority of advanced cancer patients and are associated with poor prognosis and 30 quality of life. Reversing muscle loss in tumor-bearing animal models leads to 31 improved chemotherapeutic efficacy, reduced cancer-associated morbidity, and 32 prolonged survival1,2, demonstrating that maintaining muscle mass in cancer 33 patients should be a top clinical priority. Despite a growing number of active 34 clinical trials for cancer-associated weight loss, effective therapies remain 35 elusive. Major problems hampering significant progress include the variability of 36 weight loss presentation across tumor types and stages, limited early detection of 37 lean mass/adipose tissue loss, and a poor understanding of the molecular 38 underpinnings of this complex syndrome. More work is needed to identify and 39 target alterations in skeletal muscle that contribute to overall tissue decline in 40 cancer patients. 41
Multiple factors produced by both tumor and host contribute to the wasting 42 state. Many identified 'wasting factors' are cytokines/chemokines such as TNF-43 alpha, Interleukins (including IL-1 and IL-6), CXC-proteins, and TGF-β3-6, and are 44 known to accelerate muscle atrophy, promote protein breakdown, and inhibit 45 muscle regeneration. Additionally, many of these factors are linked to 46 mitochondria dysfunction and altered cellular metabolism7. Indeed, metabolic 47 regulation of skeletal muscle function has come into focus as a major driver of 48 multiple aspects of muscle biology including catabolism, hypertrophy, and 49 regenerative capacity. Examples of metabolic processes linked to cancer-50 associated muscle wasting are: mitochondria dynamics8, mitochondria 51 biogenesis9,10, mitochondria catabolism (ie. mitophagy)11, and compromised 52 energy utilization pathways12. A more sophisticated understanding of how 53 metabolic factors contribute to cancer-associated muscle dysfunction is needed 54 to facilitate the development of novel therapies to preserve muscle mass and 55 function in cancer patients. 56 drive aspects of the atrophy phenotype37,38. Taking into account the expanding 88 role of the satellite cell in muscle wasting, the importance of metabolism in 89 cancer-associated wasting, and recent evidence implicating the oncometabolite 90 succinate in cancer cachexia17 and stem/progenitor cell function18,19, we sought 91 to characterize the effects of succinate elevation in muscle myoblast cells (in 92 vitro) and using animal models (in vivo). Studies presented herein highlight the 93 ability of an oncometabolitesuccinateto directly impact myogenesis and 94 muscle regeneration, thus underscoring the need to further explore metabolic 95 drivers of muscle wasting in order to advance anti-wasting cancer therapies. 96
METHODS 97
Animals 98
Mice were bred and housed according to NIH guidelines for the ethical treatment 99 of animals in a pathogen-free facility at the Mayo Clinic (Rochester, MN campus). 100
The Mayo Clinic Institutional Animal Care and Use Committee (IACUC) approved 101 all animal protocols and all experiments were performed in accordance with 102 relevant guidelines and regulations. Wild type mice were on the FVB background 103 (Charles River Labs) unless noted otherwise in the text or figure legends. For 104 homeostasis and regeneration assays, all mice were 3-5 months old, FVB males. 105
In these experiments, mice were administered succinate (Sigma-Aldrich) (2%) 106 and 1% sucrose (vehicle) or 1% sucrose (vehicle only) in their drinking water for 107 6-8 weeks prior to and throughout the injury time course. Muscle injury was 108 performed by injecting the left tibialis anterior muscle with 70uL BaCl2 (1.2% in 109 saline) or saline (control) and harvesting muscles 1 or 4 weeks post injury. 110
MRI imaging 111
An EchoMRI (magnetic resonance imaging) Body Composition Analyzer ( Tissue for immunostaining was placed in a sucrose sink (30%) overnight prior to 133 freezing and sectioning. Sections (8-10 um) were post-fixed in 4% 134 paraformaldehyde (PFA) for 5 minutes at room temperature prior to 135 immunostaining. Once fixed, tissue sections were permeabilized with 0.5% 136
Triton-X100 in PBS followed by blocking with 3% BSA, 0.2% Triton-X and 0.2% 137
Tween-20 in PBS. Primary antibody incubations occurred at RT for 90 minutes 138 followed by incubation with secondary antibody at RT for 30 minutes in buffer 139 described above. The following antibodies were used in this study: MF-20 140 C2C12 cells were differentiated as described above and cell pellets were 157 collected at each day post differentiation as well as prior to differentiation (day 0, 158 growth media). RNA was isolated using column purification (Qiagen) and cDNA 159 was prepared using high capacity cDNA reverse transcription kit (Applied 160 Biosystems). qPCR was preformed using BioRad CFX384 Real Time System. 161
Primer sequences are available upon request. 162
Metabolic Assays 163
A Seahorse XFe24 Analyzer (Agilent) was used to perform mitochondria stress 164 tests and energy phenotyping tests on C2C12 cells. Cells were treated with 4 or 165 8mM DM-succinate or control growth media for 16-18 hours prior to the assay. MetaboAnalyst. 212
RNA sequencing analysis 213
Sample/library preparation: Three biological replicates of control and DM-214 succinate (8mM) treated C2C12 cells were prepared for untargeted 215 metabolomics analyses as follows: cells were grown to 60% confluency and then 216 treated with 8mM succinate for 48 hours, at which time plates were washed with 217 PBS and cells were scraped and pelleted, followed by storage at -80° C. Frozen 
Statistics 242
Data are represented as the mean ± SD using GraphPad Prism unless noted 243 otherwise in the figure legends. Quantification of nuclei per MyHC+ structure was 244 analyzed using nonparametric, Mann-Whitney t-tests. Quantification of muscle 245 cross sections using minimum feret diameter measurements was analyzed by 246 non-linear regression (gaussian, least squares method) and compared between 247 conditions using an extra sum-of-squares F test. All other comparisons between 248 groups were performed using unpaired two-tailed student's t tests or multiple t 249 tests with Holm-Sidak multiple testing correction, as noted in figure legends. For 250 all analyses, a p<0.05 was considered significant (denoted with *); a p<0.01 was 251 denoted with ** unless noted otherwise in the figure legend. 252
Data availability 253
Datasets generated during the current study are available from the 254 corresponding author upon request. 255
RESULTS 256
Modeling succinate accumulation and evaluating consequences on growth and 257 atrophy 258
To evaluate the effects of succinate on in vitro myoblast function, we first 259 sought to adapt an established paradigm of intracellular succinate accumulation 260 for use in myoblast cells. Succinate has very low cell permeability in vitro, so we 261 began our studies using dimethyl-succinate (DM-succinate or DMS), a cell 262 permeable succinate analog used in prior studies to elevate intracellular 263 metabolite levels18,19. We treated proliferating C2C12 myoblasts for 48 hours with 264 two concentrations of DM-succinate, 4 mM and 8 mM, and then performed 265 targeted metabolomics to quantify levels of TCA cycle-associated metabolites. 266
We found that 8 mM DM-succinate treatment resulted in a significant increase in 267 intracellular succinate (~2.5-fold) compared to control treatment, similar in 268 magnitude to previously reported values18 and consistent with the degree of 269 succinate accumulation in wasting cancer patients17. We did not detect 270 statistically significant changes in most other TCA metabolites analyzed, with the 271 exception of small (<2 fold) but significant increases in malate and glutamate 272 ( Fig. 1A) . We chose to evaluate this dosing paradigm further to investigate the 273 effects of intracellular succinate elevation on myogenesis. Cell proliferation and 274 apoptosis are important regulators of myogenesis. To test if succinate would 275 influence either of these processes, we evaluated cells treated with three doses 276 of DM-succinate over 48 hours. We did not see significant differences in 277 proliferation over this time period, and only saw increased apoptosis rates with 278 16 mM DM-succinate treatment (Fig. 1B, C) . 279
A major feature of cancer-associated muscle wasting is myofiber atrophy due 280 to either enhanced protein catabolism or impaired protein anabolism. In 281 myoblasts exposed to DM-succinate, we did not observe an increase in mRNA 282 transcripts encoding for E3 ubiqutin ligases (MuRF1, Atrogin-1) typically 283 associated with enhanced muscle catabolism ( Fig. 1D) . We did, however, 284 observe a reduction in protein anabolism as determined by an O-propargyl-285 puromycin (OPP) incorporation assay, performed in proliferating C2C12 286 myoblasts treated with 8 mM DM-succinate for 48 hours (Fig. 1E) . Interestingly, 287 differentiated C2C12 myotubes treated with 8 mM DM-succinate for 24 hours 288 post myogenic differentiation did not exhibit statistically significant alterations in 289 mean myotube diameter ( Fig. 1F) , suggesting that the DM-succinate-associated 290 protein anabolism deficits are not sufficient to drive muscle atrophy. 291
Elevated succinate levels impair in vitro myogenesis 292
To gain a more comprehensive understanding of the molecular changes 293 associated with succinate elevation, we performed RNA sequencing (RNA-seq) 294 on proliferating C2C12 myoblasts treated with 8 mM DM-succinate for 48 hours. 295
Analysis of the transcripts involved in myogenesis and lineage specification 296
revealed widespread transcript down-regulation after exposure to DM-succinate 297 ( Fig. 2A) . These results led us to more closely investigate myogenic progression 298 by differentiating C2C12 myoblast cultures in low serum conditions for 5 days in 299 the presence or absence of 8 mM DM-succinate. In this assay, we assessed the 300 these data show that elevated succinate in muscle cells influences protein 312 anabolism and suppresses myogenic differentiation and that these changes are 313 distinct from direct myotube atrophy via enhanced protein catabolism. 314
In vivo succinate supplementation impairs skeletal muscle homeostasis 315
Defects in progenitor cell activation, expansion, differentiation, or fusion 316 compromise the regenerative capacity of skeletal muscle. Given our observations 317 that DM-succinate impairs myogenic differentiation in vitro, we next asked if 318 succinate supplementation negatively impacts in vivo skeletal muscle 319 homeostasis. Wildtype mice were either supplemented with vehicle (1% sucrose) 320 control drinking water or water with 2% succinate (+1% sucrose vehicle). We 321 found that there was no significant difference in total body weight across the 322 supplementation, or at the endpoint (Fig. 3A, B) . In addition to total body weight, 323
we longitudinally monitored body composition of the mice twice weekly for six 324 weeks using magnetic resonance imaging (MRI). Total lean mass, as measured 325 by MRI-based body composition analyses, did not show a difference between 326 vehicle and succinate-supplemented mice (Fig. 3C) . Comparisons of tibialis 327 anterior (TA) and gastrocnemius (GR) muscle wet weights after six weeks of 328 supplementation did not reveal significant differences between experimental 329 groups (Fig. 3D) . Following six weeks of succinate supplementation, we 330 harvested TA muscles and stained tissue cross sections with laminin, a protein 331 on the myofiber membrane, to evaluate myofiber size (Fig. 3E) . We quantified 332 myofiber minimum feret diameters using Myovision44 and found a statistically 333 significant decrease in the non-linear regressions fit to the histograms of 334 minimum feret diameter distribution between control and succinate supplemented 335 cohorts ( Fig. 3F) . 336
Succinate supplementation impairs skeletal muscle regeneration 337
Muscle progenitor cells are required for efficient muscle regeneration 338 following serious injury23-25. In order to challenge resident satellite cells 339 chronically exposed to elevated succinate, after six weeks of supplementation, 340
we injured TA muscles with intramuscular barium chloride injection (1.2%). At 7 341 days and 28 days post injury (dpi) we harvested TA muscle for histological 342 analysis. At 7 dpi, we observed statistically significant (p=0.0016) differences in 343 myofiber regeneration as evidenced by ~16% reduction in the mean of non-linear 344 regression curves fit to the minimum feret diameter distribution (Fig. 4A, B) . 345
Muscle regeneration post barium chloride injury is typically completed four weeks 346 post injury in healthy, adult mice. When we analyzed minimum feret diameters at 347 28 dpi, the difference in the mean of non-linear regression curves fit to the 348 minimum feret diameter distribution became more pronounced (~52% reduction, 349 p<0.0001) (Fig. 4C, D) . Injured TA muscle in succinate supplemented mice 350 exhibited large areas of poorly regenerated tissue (Fig. 4C) . To further 351 investigate the impacts of chronic succinate supplementation on the satellite cell 352 population we looked at markers of myogenic differentiation and proliferation. We 353 saw no significant difference in the number of total (PAX7+) or proliferating 354 (PAX7+KI67+) muscle progenitor cells in succinate-supplemented animals at 7-355 or 28 dpi, in concordance with in vitro proliferation data ( Fig. 4E, F; top) . At 7-356 days post injury there was no difference in the number of MYOG+ differentiating 357 muscle progenitor cells between succinate-and vehicle-supplemented mice. 358
However, we did see a significant accumulation of differentiating muscle 359 progenitor cells (MYOG+) in succinate-supplemented animals at 28 dpi, 360
indicative of stalled or incomplete myogenesis. In comparison, vehicle-361 supplemented mice had low numbers of MYOG+ cells at 28 dpi likely due to 362 effective completion of myogenesis (Fig. 4E; bottom) . Taken together, these 363 data show that succinate supplementation alters progenitor cell dynamics 364 resulting in impaired skeletal muscle homeostasis and diminished skeletal 365 muscle regeneration. 366
Succinate elevation disrupts multiple metabolic networks in muscle cells 367
Succinate is gaining traction as a metabolite capable of acting as more than a 368 substrate for succinate dehydrogenase and the respiratory chain45. Notably, 369 succinate is located at the intersection of many diverse metabolic pathways and 370 can influence a wide range of metabolic processes46,47. We performed non-371 targeted metabolomics profiling on control and 8 mM treated (48h) C2C12 372 myoblasts and found a striking number of differentially abundant metabolites 373 (DAMs) between in the two conditions (214 features with p<0.05, FC>2). Network 374 analyses of metabolic pathways associated with these DAMs implicated 375 pathways involved in amino acid and nucleotide metabolism, as well as 376 metabolic processes associated with mitochondrial metabolism and the TCA 377 cycle (Fig. 5A,B) . Considering the central role of the mitochondria in coordinating 378 cellular metabolism and the known involvement of succinate in several 379 mitochondria-coupled processes, we posited that succinate elevation could result 380 in mitochondria dysfunction. Prior evidence suggests that myogenic 381 differentiation involves metabolic rewiring characterized by increased 382 mitochondria mass and a shift towards oxidative phosphorylation48,49. To assess 383 mitochondria function, we measured cellular oxygen consumption rates (OCR) in 384 proliferating myoblasts treated with 4 mM and 8 mM DM-succinate exposed to 385 mitochondrial stressors. When treated with compounds targeting ATP synthase 386 (oligomycin), the hydrogen ion gradient (FCCP), and complex I/III 387 (Rotenone/Antimycin A), we noted altered OCR dynamics in myoblasts treated 388 with the highest dose (8 mM) of DM-succinate ( Fig. 5C ). Maximal respiration, as 389 determined by OCR measurements following the addition of the ionophore 390 FCCP, was significantly reduced (~35%) in the presence of 8 mM DM-succinate 391 ( Fig. 5D) , thus significantly decreasing mitochondria reserve capacity50 (~50% 392 reduction; Fig. 5E ). Basal respiration rates, and non-mitochondrial respiration 393 were unaffected by succinate elevation (Fig. 5F, G) . The ability of cells to 394 respond to general mitochondrial stress was further assessed using an energy 395 phenotyping test, which exposes cells to FCCP and oligomycin simultaneously 396 and measures both ECAR (extracellular acidification rate) and OCR. When 397 stressed, control cells exhibited expected increases in ECAR and OCR, whereas 398 DM-succinate treated cells responded poorly (Fig. 5H) . Taken together, these 399 data show that while elevated succinate does not grossly affect mitochondria 400 morphology or basal (resting) respiration parameters, it does impact the ability of 401 cells to maximally engage mitochondrial respiration under stressful conditions. 402
DISCUSSION 403
Mitochondria and tricarboxylic acid (TCA) cycle defects are commonly 404 observed in wasting skeletal muscle51-53. Direct alterations to TCA metabolite 405 stoichiometry could therefore, in principal, contribute to functional deficits 406 associated with muscle wasting. Indeed, multiple studies show that perturbations 407 in the succinate/alpha-ketoglutarate ratio underlie a spectrum of cellular defects 408 ranging from epigenome alterations to mitochondria deficits15,19,54. In this study, 409
we found that succinate elevation in muscle progenitor cells impaired myogenic 410 differentiation in vitro and disrupted in vivo muscle regeneration in response to 411 injury. While we did not explore the wasting-inducing potential of other 412 metabolites, we anticipate that future evaluation of metabolites as wasting-413 associated factors will reveal many new drivers of muscle wasting and will 414 prompt a re-evaluation of therapeutic strategies designed to limit cancer-415 associated weight loss. These data support the hypothesis that elevated succinate levels specifically 452 impair myogenic differentiation, an energetically demanding process that 453 challenges myoblast mitochondria. Furthermore, these studies provide evidence 454 that suppression of myogenesis is a contributing factor to cancer-associated lean 455 mass loss. 456
Our data show that in vivo succinate supplementation impairs muscle 457 morphometric parameters and regeneration properties, thus adding to the 458 growing list of studies that report metabolite-driven skeletal muscle mass and/or 459 Figure 5 
